Assanangkornchai Sawitri, Srisurapanont Manit
aDepartment of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Curr Opin Psychiatry. 2007 May;20(3):222-7. doi: 10.1097/YCO.0b013e3280fa837d.
The present review summarizes current research on the management of alcohol dependence, including pharmacotherapy, psychosocial interventions and treatment of alcohol dependence with comorbid psychiatric disorders.
Among recent studies, naltrexone has demonstrated the most consistent effect in reducing alcohol consumption in the context of behavioral therapy. In contrast to most previous studies, acamprosate did not show significant benefits on treatment outcomes relative to placebo. The combined use of naltrexone and acamprosate appeared to be safe and well tolerated but there was no additional therapeutic benefit. With the exception of topiramate, there are currently no new, effective medications for alcohol dependence. Of the psychosocial interventions, such as social behavior and network therapy, cognitive behavioral therapy, and motivational enhancement therapy, no one appears to be superior to another. Psychiatric comorbidity is common in alcohol-dependent patients; however, there are too few studies to effectively guide treatment practice.
Progress has been made with pharmacotherapy and psychosocial interventions for alcohol-dependent individuals. More research is needed, however, in developing newer medications and psychosocial interventions in alcohol-dependent populations and in those with comorbid psychiatric conditions, and to improve the strategies to engage patients in continuing care.
本综述总结了目前关于酒精依赖管理的研究,包括药物治疗、心理社会干预以及合并精神障碍的酒精依赖治疗。
在近期研究中,纳曲酮在行为疗法背景下减少酒精摄入方面显示出最一致的效果。与大多数先前研究不同,与安慰剂相比,阿坎酸在治疗结果上未显示出显著益处。纳曲酮和阿坎酸联合使用似乎安全且耐受性良好,但没有额外的治疗益处。除托吡酯外,目前尚无治疗酒精依赖的新型有效药物。在心理社会干预方面,如社交行为与网络疗法、认知行为疗法和动机增强疗法,似乎没有一种干预方法优于另一种。精神共病在酒精依赖患者中很常见;然而,有效指导治疗实践的研究太少。
在酒精依赖个体的药物治疗和心理社会干预方面已取得进展。然而,在酒精依赖人群以及合并精神疾病的人群中开发更新的药物和心理社会干预措施,以及改进促使患者持续接受治疗的策略,仍需要更多研究。